Xebio Holdings Co. Ltd. said its normalized net income for the fiscal first quarter ended June 30 was ¥49.97 per share, a decrease of 26.7% from ¥68.16 per share in the prior-year period.
Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was ¥2.25 billion, a decline of 26.7% from ¥3.07 billion in the prior-year period.
The normalized profit margin dropped to 4.3% from 6.0% in the year-earlier period.
Total revenue climbed year over year to ¥52.94 billion from ¥51.52 billion, and total operating expenses increased 5.5% from the prior-year period to ¥49.58 billion from ¥46.98 billion.
Reported net income decreased 30.3% from the prior-year period to ¥2.03 billion, or ¥44.90 per share, from ¥2.91 billion, or ¥64.45 per share.
As of Aug. 13, US$1 was equivalent to ¥102.37.